Yingmiao Liu Selected Research

Nucleotide Aptamers

1/2010	In vivo selection of tumor-targeting RNA motifs.
2/2009	Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.
1/2009	RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.
1/2008	RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.
8/2007	NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yingmiao Liu Research Topics

Disease

18	Neoplasms (Cancer) 01/2022 - 01/2006
12	Colorectal Neoplasms (Colorectal Cancer) 05/2024 - 01/2010
5	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2009
3	Pancreatic Neoplasms (Pancreatic Cancer) 05/2024 - 01/2020
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 01/2019
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2020
2	Hypoxia (Hypoxemia) 01/2022 - 01/2008
2	Hypertension (High Blood Pressure) 01/2022 - 01/2022
2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Hemorrhage 01/2021 - 10/2020
2	Thrombosis (Thrombus) 01/2021 - 02/2020
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2009
2	Carcinogenesis 01/2020 - 01/2009
2	Kidney Neoplasms (Kidney Cancer) 01/2020 - 01/2019
2	Colonic Neoplasms (Colon Cancer) 03/2013 - 01/2010
2	Adenocarcinoma of Lung 08/2007 - 01/2006
1	Prostatic Neoplasms (Prostate Cancer) 02/2024
1	Adenocarcinoma 01/2022
1	Rectal Neoplasms (Rectal Cancer) 01/2022
1	Periodontitis 01/2022
1	Thromboembolism 01/2021
1	Triple Negative Breast Neoplasms 01/2021
1	Familial cerebral cavernous malformation 01/2021
1	Vascular Malformations 01/2021
1	Arteriovenous Malformations (Arteriovenous Malformation) 01/2021
1	Hereditary Hemorrhagic Telangiectasia 01/2021
1	Colitis 02/2020
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2020
1	Disease Progression 01/2020
1	Ovarian Epithelial Carcinoma 01/2020
1	Squamous Cell Carcinoma of Head and Neck 07/2019
1	Multiple Myeloma 06/2018
1	Polyps 12/2017
1	Medulloblastoma 09/2017
1	Craniocerebral Trauma (Head Injury) 02/2017

Drug/Important Bio-Agent (IBA)

16	Biomarkers (Surrogate Marker)IBA 02/2024 - 04/2013
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2024 - 08/2007
9	Bevacizumab (Avastin)FDA Link 02/2024 - 04/2013
8	Proteins (Proteins, Gene)FDA Link 05/2024 - 02/2009
7	EndoglinIBA 01/2021 - 06/2014
6	carotuximabIBA 01/2021 - 06/2014
5	Nucleotide AptamersIBA 01/2010 - 08/2007
4	PhosphatidylserinesIBA 01/2022 - 06/2018
4	regorafenibIBA 01/2022 - 10/2019
4	CytokinesIBA 01/2022 - 07/2019
3	Monoclonal AntibodiesIBA 01/2021 - 01/2019
3	NF-kappa B (NF-kB)IBA 01/2008 - 01/2006
2	Long Noncoding RNAIBA 05/2024 - 12/2023
2	Capecitabine (Xeloda)FDA Link 01/2022 - 04/2013
2	Angiopoietin-2IBA 01/2022 - 01/2022
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022 - 01/2022
2	Blood Proteins (Serum Proteins)IBA 01/2022 - 01/2022
2	Axitinib (AG 013736)IBA 01/2021 - 01/2019
2	Fibrinogen (Factor I)FDA Link 01/2021 - 10/2020
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2008
2	Glycoproteins (Glycoprotein)IBA 10/2014 - 02/2009
1	Prednisone (Sone)FDA LinkGeneric 02/2024
1	Docetaxel (Taxotere)FDA Link 02/2024
1	cabozantinibIBA 03/2022
1	Panitumumab (Vectibix)FDA Link 03/2022
1	LigandsIBA 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	prothrombinase complexIBA 01/2022
1	lenvatinibIBA 01/2022
1	inhibin AIBA 01/2022
1	Inhibins (Inhibin)IBA 01/2022
1	Activins (Activin)IBA 01/2022
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021
1	((3- (bis(2- chloroethyl)amino)- 4- methylphenyl)hydroxymethane)bisphosphonic acidIBA 01/2021
1	Neutralizing AntibodiesIBA 12/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2020
1	adhesion receptorIBA 10/2020
1	Tyrosine Kinase InhibitorsIBA 10/2020
1	Deoxyribonucleases (DNase)FDA Link 02/2020
1	Dextrans (Dextran)FDA Link 02/2020
1	SodiumIBA 02/2020
1	Drinking WaterIBA 02/2020
1	AntibodiesIBA 01/2020
1	Carboplatin (JM8)FDA LinkGeneric 01/2020
1	olaparibIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	durvalumabIBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2020
1	PlatinumIBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020
1	ascrinvacumabIBA 10/2019
1	Activin Receptors (Activin Receptor)IBA 10/2019
1	Dexamethasone (Maxidex)FDA LinkGeneric 06/2018
1	Immunomodulating AgentsIBA 06/2018
1	Adenosine Triphosphate (ATP)IBA 12/2017
1	EnzymesIBA 12/2017
1	Cytidine Diphosphate Choline (Citicoline)IBA 02/2017

Therapy/Procedure

8	Therapeutics 01/2022 - 02/2009
7	Drug Therapy (Chemotherapy) 05/2024 - 01/2008
2	Neoadjuvant Therapy 01/2022 - 01/2021
1	Castration 02/2024
1	Adjuvant Chemotherapy 01/2022
1	Radiotherapy 01/2022
1	Intravenous Injections 01/2021